Skip to main content

Table 1 Summary of the 23 CVOTs included

From: The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs

Trial/year of publication Study drug/mean follow up (years) Participants (n) Age mean/median age (years) Male sex (n, %) Participants with prior CV disease (%) Primary outcome Study funder
DPP-4 inhibitors
 SAVOR-TIMI53/2013 Saxagliptin/2.1 16,492 65 11,050 (67%) 78 MACE AstraZeneca
 EXAMINE/2013 Alogliptin/1.5 5380 61 3658 (68%) 100 MACE Takeda
 TECOS/2015 Sitagliptin/3.0 14,523 65 10,311 (71%) 100 MACE Merck
 CARMELINA/2019 Linagliptin/2.2 6979 66 4788 (68.6%) 57 MACE Boehringer/Lilly
GLP-1RA
 ELIXA, 2015 Lixisenatide/2.1 6068 60.3 3174 (69.3%) 100 MACE Sanofi
 LEADER/2016 Liraglutide/3.8 9340 64.3 6003 (64.3%) 81 MACE NovoNordisk
 SUSTAIN-6/2016 Semaglutide/2.1 3297 64.6 2002 (60.7%) 83 MACE NovoNordisk
 EXSCEL/2017 Exenatide/3.2 14,752 62 9149 (62%) 73.1 MACE Amylin
 HARMONY/2018 Albiglutide/1.6 9463 64.1 6569 (69.4%) 100 MACE GlaxoSmithKline
 REWIND/2019 Dulaglutide/5.4 9901 66.2 5312 (53.7%) 31.4 MACE Boehringer/Lilly
 PIONEER 6 /2019 Semaglutide/1.3 3183 66.0 2176 (68.4%) 84.7 MACE NovoNordisk
 AMPLITUDE-O/2021 Epfeglenatide/1.8 4076 64.5 2732 (67%) 89.6 MACE SANOFI
SGLT-2 inhibitors
 EMPA-REG/2015 Empagliflozin/3.1 7020 63.2 5016 (71.5%) 99 MACE Boehringer/Lilly
 CANVAS/2017 Canagliflozin/2.4 10,142 63.2 6509 (64.2%) 66 MACE Janssen
 DECLARE/2019 Dapagliflozin/4.2 17,16 63.8 10,738 (62.6%) 40.6 MACE AstraZeneca
 CREDENCE/2019 Canagliflozin/2.6 4401 63 2907 (66.1%) 50.4 Composite renal Janssen
 DAPA-HF/2019 Dapagliflozin/1.5 4744 66 3131 (66%) 100 HHF or CV death AstraZeneca
 VERTIS-CV/2020 Ertugliflozin/3.5 8246 64.4 5769 (70%) 100 MACE Merck
 DAPA-CKD/2020 Dapagliflozin/2.4 4304 61.8 2879 (66.9%) 38 Composite renal AstraZeneca
 EMPEROR-R/2020 Empagliflozin/1.3 3730 66.8 2837 (76%) 100 HHF or CV death Boehringer/Lilly
 SCORED/2021 Sotagliflozin/1.3 10,584 69 5896 (55.7%) NA HHF or CV death Sanofi/Lexicon
 SOLOIST-WHF/2021 Sotagliflozin/0.75 1222 70 810 (63.3%) 100 HHF or CV death Sanofi/Lexicon
 EMPEROR-P/2021 Empagliflozin/2.2 5988 71.9 3317 (55.4%) 100 HHF or CV death Boehringer/Lilly
  1. HHF hospitalization for heart failure